Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare giant, has entered into a definitive agreement to acquire global rights to NM26, a first-in-class bispecific antibody (BsAb) for the treatment of atopic dermatitis (AD), from Switzerland-based Numab Therapeutics. The transaction, valued at $1.25 billion in cash, is anticipated to conclude in the second half of 2024, subject to the fulfillment of customary closing conditions.
NM26 is designed to target the IL-4R alpha subunit (IL-4Rα) and IL-31, which play pivotal roles in Th2-mediated skin inflammation and skin itch, respectively. The drug candidate is on track to advance into Phase II of its development program for AD and holds promise for the treatment of other inflammatory skin diseases.- Flcube.com
